FDA seeks to accelerate pace of biosimilar drug approvals

4 October 2018
biosimilars_samples_large

Kevin Noonan, a partner with McDonnell Boehnen Hulbert & Berghoff, provides commentary on the US Food and Drug Administration's (FDA) Biosimilars Action Plan in an Expert View piece.

After an uncharacteristic period of delay (at least compared with Europe), the USA enacted a biosimilar approval pathway entitled the Biologics Price Competition and Innovation Act (BPCIA) as part of the Affordable Care Act (Obamacare) in 2010.

The act was put at risk with the Supreme Court challenge in  National Federation of Independent Business v. Sebelius, 567 US 519 (2012) (because the biosimilars provisions were not severable from the challenged portions of the act), but Chief Justice Roberts’ majority opinion affirming the constitutionality of the act preserved the pathway and permitted the FDA to continue to develop regulations to put it into practice.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biosimilars